Pacira BioSciences, Inc. (PCRX)
- Previous Close
26.10 - Open
25.98 - Bid 25.93 x 100
- Ask 26.12 x 100
- Day's Range
25.92 - 26.29 - 52 Week Range
25.76 - 48.60 - Volume
169,060 - Avg. Volume
496,382 - Market Cap (intraday)
1.21B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
29.24 - EPS (TTM)
0.89 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
46.40
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
www.pacira.com711
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PCRX
Performance Overview: PCRX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PCRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PCRX
Valuation Measures
Market Cap
1.21B
Enterprise Value
1.52B
Trailing P/E
29.33
Forward P/E
9.49
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.01
Price/Book (mrq)
1.39
Enterprise Value/Revenue
2.25
Enterprise Value/EBITDA
9.84
Financial Highlights
Profitability and Income Statement
Profit Margin
6.22%
Return on Assets (ttm)
3.35%
Return on Equity (ttm)
5.10%
Revenue (ttm)
674.98M
Net Income Avi to Common (ttm)
41.95M
Diluted EPS (ttm)
0.89
Balance Sheet and Cash Flow
Total Cash (mrq)
278.58M
Total Debt/Equity (mrq)
67.35%
Levered Free Cash Flow (ttm)
107.15M
Research Analysis: PCRX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: PCRX
PCRX: Lowering target price to $28.00
PACIRA BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetPCRX: What does Argus have to say about PCRX?
PACIRA BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetPCRX: What does Argus have to say about PCRX?
PACIRA BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetPCRX: Lowering target price to $30.00
PACIRA BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice Target